Merck/Schering-Plough Press Releases
Press Releases
Information About the SEAS Study
Information About the ENHANCE Trial
Frequently Asked Questions
Home
About Us
Patient Assistance Program
Responsibility and Compliance
Company News
Press Releases
Information About the SEAS Study
Information About the ENHANCE Trial
Frequently Asked Questions
MERCK/Schering-Plough Pharmaceuticals

Information About the ENHANCE Trial

Merck / Schering-Plough Press Releases

Merck/Schering-Plough Pharmaceuticals Comments on Results of the ENHANCE Study - 03/30/08
Results from ENHANCE Study - 03/30/08
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial – 01/25/08
ENHANCE Chronology – 01/25/08
Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial – 01/14/08
Merck/Schering-Plough Pharmaceuticals Provides Update on ENHANCE Trial – 11/19/07

Prescribing Information for VYTORIN® (ezetimibe/simvastatin)
Patient Product Information for VYTORIN

Prescribing Information for ZETIA® (ezetimibe)
Patient Product Information for ZETIA

Information From Merck and Schering-Plough

Message to Patients about Recent News on VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe) – 01/19/08

Prescribing Information for VYTORIN
Patient Product Information for VYTORIN

Prescribing Information for ZETIA
Patient Product Information for ZETIA

FDA Communications 

Update of Safety Review: Follow-up to the January 25, 2008 Early Communication about an Ongoing Data
Review for Ezetimibe/Simvastatin (marketed as VYTORIN), Ezetimibe (marketed as ZETIA), and Simvastatin
(marketed as Zocor)
Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as VYTORIN),
Ezetimibe (marketed as ZETIA), and Simvastatin (marketed as Zocor)
Transcript of FDA Press Conference on Early Communication about an Ongoing Review of VYTORIN

Prescribing Information for VYTORIN
Patient Product Information for VYTORIN

Prescribing Information for ZETIA
Patient Product Information for ZETIA